Clinical trials: Adult Atopic Dermatitis
Atopic Dermatitis
A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by…
- Trial name
- ADMIRE (NCT05451316)
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and…
- Trial name
- TRuE-AD4 (NCT06238817)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 241 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
- Trial name
- NCT03745638
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 631 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis (AD)
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
The purpose of this 14-day, two phase clinical study is to test the tolerance of a new over-the-counter moisturizing balm on subjects with eczema.
- Trial name
- NCT02357940
- Testing
- Experimental Product
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis
This study will evaluate the efficacy and safety of two concentrations (0.3 percent [%] and 1%) of twice daily LNK01004 ointment for the topical treatment in adult subjects with atopic dermatitis.
- Trial name
- NCT07071610
- Testing
- LNK01004 ointment 0.3%, LNK01004 ointment 1.0%, Vehicle
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Atopic Dermatitis, Atopic
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
- Trial name
- NCT07599813
- Testing
- Camoteskimab
- Where
- 85 sites in United States, Bulgaria and 6 more
- Volunteers
- 280 people
- Sponsor
- Apollo Therapeutics Ltd
Atopic Dermatitis, Eczema, Atopic
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema.
- Trial name
- NCT07216027
- Testing
- PF-08049820
- Where
- 52 sites in United States, Bulgaria and 7 more
- Volunteers
- 165 people
- Sponsor
- Pfizer
Atopic Dermatitis
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the…
- Trial name
- NCT03725722
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 251 people
- Sponsor
- LEO Pharma
Dermatitis, Atopic, Asthma
A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants
The purpose of this study is to characterize the cell (the basic building block of all living things) populations and inflammatory (pain and swelling) mediator responses in suction skin blister fluid after allergic skin reaction…
- Conditions
- Dermatitis, Atopic, Asthma, Healthy
- Trial name
- NCT02343783
- Testing
- Allergic Skin Reaction (ASR) Testing and Skin Blister Induction
- Where
- 7 sites in Belgium, Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis
Scratching Validation Study
Single center, analyst-blinded, study comparing the scratching events identified via an actigraphy scoring algorithm versus manual scoring of an overnight video recording, undertaken in a sample of 40 adult patients with atopic…
- Trial name
- NCT05137093
- Testing
- Actigraphy Device
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Atopic Dermatitis
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are…
- Trial name
- GECKO (NCT03864627)
- Testing
- MOR106
- Where
- 14 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
- Trial name
- ADapt (NCT05369403)
- Testing
- Lebrikizumab
- Where
- 37 sites in United States
- Volunteers
- 86 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
This is an open-label, single-sequence DDI study designed to examine the effects of dupilumab on the pharmacokinetics of selected cytochrome P450 substrates in adult patients with moderate to severe AD.
- Trial name
- NCT02647086
- Testing
- Dupilumab, Midazolam, Omeprazole
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adolescent and adult subjects with mild to moderate AD.
- Trial name
- NCT03571620
- Testing
- Q301 Cream, Vehicle
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- Qurient Co., Ltd.
Moderate-to-severe Atopic Dermatitis
A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of QLS12010 Capsules in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07344051
- Testing
- QLS12010
- Volunteers
- 160 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis (AD)
A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis
This Phase 1 study will assess NOR-101, an investigational study drug, in two parts. Part 1 is a randomized, blinded study comparing single and multiple doses of NOR-101 with placebo in healthy adults.
- Trial name
- POLARIS-1 (NCT07904689)
- Testing
- NOR-101
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- North Immunology Inc.
Moderate to Severe Atopic Dermatitis
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT03568162
- Testing
- ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3
- Where
- 83 sites in United States, Canada and 3 more
- Volunteers
- 462 people
- Sponsor
- Ichnos Sciences SA
Atopic Dermatitis
Quality of Life Study in Adults With Facial Eczema
This study is not being conducted in the US. The study consists of a 4 week double blind treatment period. All patients meeting the inclusion/exclusion criteria will enter the study at day 0 and be randomized into either…
- Trial name
- NCT00120302
- Testing
- Pimecrolimus
- Where
- United Kingdom
- Volunteers
- 76 people
- Sponsor
- Novartis
Atopic Dermatitis
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with…
- Trial name
- NCT03738423
- Testing
- REGN3500
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 129 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD)…
- Trial name
- AD Up (NCT03568318)
- Testing
- Upadacitinib, Topical corticosteroids (TCS)
- Where
- 193 sites in United States, Australia and 22 more
- Volunteers
- 1,533 people
- Sponsor
- AbbVie